Article
BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation.
Theranostics - 1 Jan 2020
Yin Weimin, Zhao Yuge, Kang Xuejia, Zhao Pengfei, Fu Xuhong, Mo Xiaopeng, Wang Yakun, Huang Yongzhuo
Abstract excerpt
EGFR TKI therapy has become a first-line regimen for non-small cell lung cancer (NSCLC) patients with EGRF mutations. However, there are two big challenges against effective therapy--the secondary EGFR mutation-associated TKI resistance and brain metastasis (BMs) of lung cancer. The BMs is a major cause of death for advanced NSCLC patients, and the treatment of BMs with TKI resistance remains difficult. Methods:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.